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BACKGROUND
The World Health Organization recommends not performing transfusions in African 
children hospitalized for uncomplicated severe anemia (hemoglobin level of 4 to 6 g 
per deciliter and no signs of clinical severity). However, high mortality and readmission 
rates suggest that less restrictive transfusion strategies might improve outcomes.
METHODS
In this factorial, open-label, randomized, controlled trial, we assigned Ugandan and 
Malawian children 2 months to 12 years of age with uncomplicated severe anemia 
to immediate transfusion with 20 ml or 30 ml of whole-blood equivalent per kilogram 
of body weight, as determined in a second simultaneous randomization, or no immedi-
ate transfusion (control group), in which transfusion with 20 ml of whole-blood equiva-
lent per kilogram was triggered by new signs of clinical severity or a drop in hemoglobin 
to below 4 g per deciliter. The primary outcome was 28-day mortality. Three other 
randomizations investigated transfusion volume, postdischarge supplementation with 
micronutrients, and postdischarge prophylaxis with trimethoprim–sulfamethoxazole.
RESULTS
A total of 1565 children (median age, 26 months) underwent randomization, with 778 
assigned to the immediate-transfusion group and 787 to the control group; 984 children 
(62.9%) had malaria. The children were followed for 180 days, and 71 (4.5%) were lost 
to follow-up. During the primary hospitalization, transfusion was performed in all the 
children in the immediate-transfusion group and in 386 (49.0%) in the control group 
(median time to transfusion, 1.3 hours vs. 24.9 hours after randomization). The mean 
(±SD) total blood volume transfused per child was 314±228 ml in the immediate-
transfusion group and 142±224 ml in the control group. Death had occurred by 28 
days in 7 children (0.9%) in the immediate-transfusion group and in 13 (1.7%) in the 
control group (hazard ratio, 0.54; 95% confidence interval [CI], 0.22 to 1.36; P = 0.19) and 
by 180 days in 35 (4.5%) and 47 (6.0%), respectively (hazard ratio, 0.75; 95% CI, 0.48 to 
1.15), without evidence of interaction with other randomizations (P>0.20) or evidence of 
between-group differences in readmissions, serious adverse events, or hemoglobin recov-
ery at 180 days. The mean length of hospital stay was 0.9 days longer in the control group.
CONCLUSIONS
There was no evidence of differences in clinical outcomes over 6 months between 
the children who received immediate transfusion and those who did not. The triggered-
transfusion strategy in the control group resulted in lower blood use; however, the 
length of hospital stay was longer, and this strategy required clinical and hemoglo-
bin monitoring. (Funded by the Medical Research Council and Department for Inter-
national Development; TRACT Current Controlled Trials number, ISRCTN84086586.)
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S
evere anemia (hemoglobin level <6 g 
per deciliter) is a leading cause of hospital 
admission among children in sub-Saharan 
Africa.1,2 Outcomes remain unsatisfactory, with 
high reported in-hospital mortality (9 to 10%)2,3 
and 6-month mortality (12%)4 and high rates of 
readmission.4 Given the major burden of pediat-
ric anemia on health services, coupled with 
scarce resources of donated blood (<5 units donat-
ed per 1000 population per year, despite sub-
stantial external funding),5 the guidelines of the 
World Health Organization (WHO) encourage 
approaches for restrictive transfusion — specifi-
cally, not performing transfusion in children in 
stable condition who have a hemoglobin level of 
4 to 6 g per deciliter.6 The underpinning evidence 
on which the WHO guidelines are based is weak,7 
and adherence to the guidelines is poor8,9 and 
hampered by inconsistent recommendations re-
garding the hemoglobin threshold for transfu-
sion in patients with malaria. There is a lack of 
guidance on postadmission strategies for clini-
cal and hemoglobin monitoring to identify chil-
dren who have new signs of clinical severity that 
warrant transfusion.6
In the Transfusion and Treatment of Severe 
Anemia in African Children Trial (TRACT), we 
compared four interventions. Here, we compare 
immediate transfusion with no immediate trans-
fusion, in which transfusion was triggered by 
the development of new signs of clinical severity 
or a drop in the hemoglobin level to below 4 g 
per deciliter, in children with uncomplicated 
severe anemia.10
Me thods
Trial Design
We performed an open-label, multicenter, facto-
rial, randomized, controlled trial at three hospi-
tals in Uganda and one hospital in Malawi. In the 
part reported here, children 2 months to 12 years 
of age were eligible if they were hospitalized for 
uncomplicated severe anemia (defined as a hemo-
globin level of 4 to 6 g per deciliter and no signs 
of clinical severity [i.e., no evidence of reduced 
level of consciousness, respiratory distress, acute 
hemoglobinuria,11 or reported sickle cell disease]). 
Children who had known chronic disease (kid-
ney or liver failure, malignant conditions, or con-
genital heart disease) or who were admitted for 
burns, trauma, or surgery were excluded, as were 
children who had previous transfusions during 
the same hospitalization or who were exclusively 
breast-fed. Further details are provided in the 
Methods section in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org.
The children were randomly assigned in a 1:1 
ratio to undergo immediate transfusion or no im-
mediate transfusion (control group). However, 
because we also evaluated the effects of transfu-
sion volume (see the accompanying article by 
Maitland et al.12 in this issue of the Journal), the 
children in the immediate-transfusion group 
underwent a second randomization in which 
they were assigned in a 1:1 ratio to receive 20 ml 
of whole blood (or 10 ml of packed or settled 
cells13) or 30 ml of whole blood (or 15 ml of 
packed or settled cells13) per kilogram of body 
weight. The children underwent simultaneous 
factorial randomization to receive adjunctive mi-
cronutrient supplementation or iron folate alone 
(usual care) for 3 months after discharge and to 
receive prophylaxis with trimethoprim–sulfa-
methoxazole (donated by Cipla) or no trimetho-
prim–sulfamethoxazole for 3 months after dis-
charge (not reported here).
In the current report, the data from the chil-
dren in the immediate-transfusion group who 
received 20 ml or 30 ml of whole-blood equiva-
lent (whole blood or packed or settled cells) per 
kilogram were pooled for prespecified compari-
sons of the randomization groups. Children with 
signs of clinical severity, a hemoglobin level of 
less than 4 g per deciliter (profound anemia), 
or both at screening were also randomly assigned 
to receive 20 ml or 30 ml of whole-blood equiva-
lent per kilogram; the results of this second 
randomization are reported in the accompany-
ing article by Maitland et al.12 The ethics com-
mittees of Imperial College London (London), 
Makerere University (Kampala, Uganda), and the 
College of Medicine (Blantyre, Malawi) approved 
the protocol, which is available at NEJM.org. All 
the authors vouch for the completeness and ac-
curacy of the data and for the fidelity of the 
trial to the protocol, and all the authors partici-
pated in writing the manuscript.
Screening and Randomization
At screening, the hemoglobin level was measured 
in children with signs or symptoms of severe 
anemia (e.g., severe pallor14) with the use of the 
A Quick Take is 
available at 
NEJM.org 
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HemoCue system,15 and a clinical assessment was 
performed. Written informed consent was ob-
tained from the parents or guardians before 
randomization. When written informed consent 
could not be obtained, the ethics committees 
approved oral assent, with delayed written in-
formed consent provided as soon as practical.16 
Randomization was stratified according to trial 
center alone, since no child in this randomiza-
tion had severity features. The statistician in 
London generated and kept the sequential ran-
domization list, which was computer-generated 
with the use of variably sized permuted blocks. 
Randomization was performed with the use of 
consecutively numbered packets that contained 
randomized links to opaque, sealed envelopes, a 
process that ensured concealment of the trial-
group assignments. Further details are provided 
in the Methods section in the Supplementary 
Appendix.
Procedures
Children were treated in general pediatric wards; 
ventilatory facilities were unavailable. Each tri-
al center was provided with basic infrastructure 
support for emergency care; patient monitors; 
and bedside hemoglobin, glucose, and lactate 
point-of care tests. Local blood-transfusion ser-
vices provided blood free of charge; the blood 
was prescreened for transfusion-transmissible in-
fections and was prepared with the use of stan-
dard procedures, but without leukocyte reduc-
tion.17 Second transfusions, if indicated among 
the children in the immediate-transfusion group, 
were performed with the originally assigned 
transfusion volume. Additional transfusions with 
20 ml of whole-blood equivalent per kilogram 
(irrespective of the randomly assigned transfu-
sion volume) were performed in the children in the 
immediate-transfusion group who had already 
received two transfusions if they continued to 
meet the criteria for transfusion or in the chil-
dren in the control group if new signs of clinical 
severity developed or if they had a drop in the 
hemoglobin level to below 4 g per deciliter. Furo-
semide or other diuretics were not prescribed. 
Other treatments, including antimalarial and 
antibiotic agents, were administered according 
to national guidelines.
Bedside observations were performed at ad-
mission, every 30 minutes for the first 2 hours, 
and then 4, 8, 16, 24, and 48 hours after initia-
tion of the first transfusion (immediate-transfu-
sion group) or after randomization (control group). 
The hemoglobin level was assessed with the use 
of the HemoCue system every 8 hours during the 
first 24 hours and then at 48 hours or if trig-
gered by clinical deterioration. The children were 
actively monitored for serious adverse events, 
particularly suspected cardiac or pulmonary over-
load or transfusion-related events; monitoring 
was performed according to the modified guide-
lines recommended by the Serious Hazards of 
Transfusion initiative in the United Kingdom.18 
After discharge, the children were clinically as-
sessed and the hemoglobin level measured at 28, 
90, and 180 days after randomization. Children 
exited the trial at 180 days. The clinicians were 
aware of the treatment-group assignments, but 
the laboratory tests were performed in a blinded 
manner.
Outcomes
The primary outcome was mortality at 28 days 
after randomization. Secondary outcomes were 
mortality at 48 hours, 90 days, and 180 days; 
development of new profound anemia (hemoglo-
bin level <4 g per deciliter) during the primary 
hospitalization or severe anemia (hemoglobin 
level <6 g per deciliter) after discharge; hospital 
readmission; the percentage of children who had 
correction of anemia (defined as hemoglobin re-
covery to a level >9 g per deciliter19 according to 
the WHO guidelines6); suspected transfusion re-
actions (febrile reactions and transfusion-related 
acute lung injury); serious adverse events; and 
cost and cost-effectiveness. Adverse events were 
graded according to the Common Toxicity Crite-
ria for Adverse Events, version 4.0.20 An indepen-
dent end-point review committee reviewed the 
cause of death, suspected transfusion reactions, 
suspected respiratory and neurologic events, and 
allergic reactions in a blinded manner.
Statistical Analysis
We determined that 1553 children would need to 
be enrolled for the trial to have 80% power to 
detect a 50% relative difference in 28-day mor-
tality, from 9.0%2,3 in the control group to 4.5% 
in the immediate-transfusion group, assuming 
that 6% of the children would be lost to follow-
up by 6 months (allowing for different timing of 
the primary outcomes in the other randomiza-
tions), at a two-sided alpha level of 0.013 (four 
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comparisons across randomizations, as detailed 
in the Methods section in the Supplementary Ap-
pendix). An independent data monitoring com-
mittee reviewed the interim data at three annual 
meetings with the use of the Haybittle–Peto 
criterion (P<0.001). The randomization groups 
were compared according to the intention-to-treat 
principle with the use of log-rank tests or com-
peting-risks methods for time-to-event outcomes, 
exact tests for binary outcomes, and generalized-
estimating equations with independent working 
correlation for global tests of repeated measures. 
The primary analyses of each outcome were 
stratified according to the same stratification 
factor used in randomization. In the economic 
analysis, costs (in U.S. dollars in 2018) and 
health outcomes (in life-years gained) over a 
period of 180 days were estimated with the use 
of health care utilization rates and unit costs for 
each country. Analyses were performed with the 
use of Stata software, version 15.1 (StataCorp), 
and R software, version 3.5.1 (R Foundation for 
Statistical Computing). The 95% confidence in-
tervals were not adjusted for multiple testing. 
Further details of the statistical analysis are 
provided in the Methods section in the Supple-
mentary Appendix.
R esult s
Patients
Between September 17, 2014, and May 15, 2017, 
a total of 1565 children underwent randomiza-
tion, with 778 children assigned to the immediate-
transfusion group (390 were assigned to receive 
20 ml and 388 to receive 30 ml of whole-blood 
equivalent per kilogram) and 787 to the control 
group; all children who underwent randomiza-
tion were included in all analyses (Fig. 1). The 
characteristics of the children at baseline were 
balanced between the randomization groups 
(Table 1, and Table S1 in the Supplementary Ap-
pendix). A total of 984 children (62.9%) had Plas-
modium falciparum malaria, but human immunode-
ficiency virus infection, culture-proven bacteremia, 
and severe malnutrition were uncommon (<4%). 
Although children with known sickle cell dis-
ease were ineligible, the condition was identified 
in 7 children after randomization. At trial com-
pletion, batch genotyping confirmed sickle cell 
disease in 340 of 1549 children (21.9%).
Adherence
Transfusion was performed during the primary 
hospitalization in 778 of the 778 children (100%) 
in the immediate-transfusion group and in 386 
of the 787 children (49.0%) in the control group. 
The median times to transfusion after randomiza-
tion were 1.3 hours (interquartile range, 0.9 to 
1.7) in the immediate-transfusion group and 24.9 
hours (interquartile range, 9.2 to 49.8) in the con-
trol group (Fig. S1 and Table S2 in the Supple-
mentary Appendix). The major trigger for trans-
fusion among the children in the control group 
was a drop in the hemoglobin level to below 4 g 
per deciliter (295 of 386 [76.4%]); 57 children 
(14.8%) had a new sign of clinical severity, and 
7 (1.8%) received a new diagnosis of sickle cell 
disease. Of the 386 transfusions performed in the 
control group, 3 (0.8%) were performed before 
48 hours and 24 (6.2%) after 48 hours in children 
who had a hemoglobin level of 4 to 6 g per deci-
liter at the last measurement and no new recorded 
signs of severity. Only 5 children (0.6%) in the 
control group who met the transfusion criteria 
did not receive one.
A total of 766 children (98.5%) in the imme-
diate-transfusion group and 379 (98.2%) in the 
control group received their first transfusion with a 
volume of whole-blood equivalent that was within 
3 ml per kilogram above or below their assigned 
transfusion volume. The first transfusion was with 
whole blood in 395 children (50.8%) in the imme-
diate-transfusion group and in 218 (56.5%) in the 
control group. The median storage age of the blood 
was 12 days (interquartile range, 6 to 19) in the 
immediate-transfusion group and 11 days (inter-
quartile range, 6 to 18) in the control group. A 
total of 748 children (96.1%) in the immediate-
transfusion group and 346 (89.6%) in the control 
group received a single transfusion; in the first 
48 hours, the maximum number of transfusions 
performed was four in the immediate-transfusion 
group and two in the control group (Table S2 in 
the Supplementary Appendix). During the primary 
hospitalization, the mean (±SD) total volume of 
whole-blood equivalent transfused per child was 
314±228 ml in the immediate-transfusion group 
and 142±224 ml in the control group.
Mortality
Vital status was known for 1556 children (99.4%) 
at day 28 (primary outcome) and for 1494 children 
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Figure 1. Screening, Randomization, and Follow-up.
In the control group (no immediate transfusion), transfusion with 20 ml of whole-blood equivalent per kilogram  
of body weight was triggered by the development of new signs of clinical severity, which included impaired con-
sciousness (prostration or unconsciousness), increased difficulty in breathing (respiratory distress), hemoglobinuria 
(grade 6 or higher) in the current illness, or a hemoglobin level of less than 4 g per deciliter. The data regarding the 
children who were lost to follow-up are presented for days 0 through 28 and days 0 through 180 days (i.e., the data 
regarding children lost to follow-up by 28 days are a subset of the data of those lost to follow-up by 180 days). Screen-
ing did not take place on the days when there was no available blood for transfusion.
1565 Underwent randomization
6171 Patients were assessed for eligibility
2154 Were excluded
1415 Did not have anemia
329 Had parent or guardian who was
not able or willing to give consent
102 Had parent or guardian who was
 unable to commit to follow-up
93 Did not have blood available
54 Were not in age range
50 Had a terminal illness or renal, liver,
or heart failure
34 Were breast-feeding
19 Were admitted for surgery
5 Died during screening
53 Had unknown reason
2452 Had signs of clinical severity and
were therefore only eligible for the
second factorial randomization
according to transfusion blood volume
778 Were assigned to the immediate-
transfusion group (388 were assigned to
receive 30 ml/kg of whole-blood equivalent
and 390 to receive 20 ml/kg)
787 Were assigned to the control group
778 Were included in the analyses 787 Were included in the analyses
778 Received transfusion
5 Were lost to follow-up by 28 days
1 Left center with parent or guardian
without notice
4 Could not be traced
37 Were lost to follow-up by 180 days
1 Was withdrawn
1 Left center with parent or guardian
without notice
3 Moved away
3 Had parent or guardian who lost 
interest in trial or had family
problems
29 Could not be traced
386 Received transfusion
4 Were lost to follow-up by 28 days
1 Withdrew
3 Left center with parent or guardian
without notice
34 Were lost to follow-up by 180 days
1 Was withdrawn
3 Left center with parent or guardian
without notice
6 Moved away
24 Could not be traced
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(95.5%) at day 180 (end of follow-up). By day 28, 
death had occurred in 7 children (0.9%) in the 
immediate-transfusion group (6 [0.8%] who 
received 20 ml and 1 [0.1%] who received 30 ml 
of whole-blood equivalent per kilogram) and in 
13 children (1.7%) in the control group (hazard 
ratio, 0.54; 95% confidence interval [CI], 0.22 to 
1.36; P = 0.19) (Table 2 and Fig. 2A, and Fig. S2 
in the Supplementary Appendix). Of the 13 chil-
dren in the control group who died, 10 had re-
ceived a transfusion a median of 9.0 hours (inter-
quartile range, 6.8 to 30.6) after randomization 
Characteristic
Immediate-Transfusion Group 
(N = 778)
Control Group 
(N = 787)
Total 
(N = 1565)
Median age (IQR) — mo 27 (13–50) 26 (12–50) 26 (12–50)
Male sex — no. (%) 440 (56.6) 442 (56.2) 882 (56.4)
Median hemoglobin level (IQR) — g/dl 5.2 (4.5–5.7) 5.1 (4.6–5.7) 5.1 (4.6–5.7)
Median weight (IQR) — kg 10.3 (8.4–14.0) 10.5 (8.1–14.5) 10.4 (8.2–14.2)
Median circumference of mid upper arm (IQR) — cm 14.2 (13.3–15.1) 14.2 (13.4–15.5) 14.2 (13.4–15.2)
Median heart rate (IQR) — beats/min 144 (130–157) 145 (131–156) 144 (130–157)
History of fever in current illness — no. (%) 749 (96.3) 757 (96.2) 1506 (96.2)
Median axillary temperature at screening (IQR) — °C† 37.1 (36.7–37.8) 37.1 (36.6–37.8) 37.1 (36.7–37.8)
Fever — no. (%) 252 (32.4) 269 (34.2) 521 (33.3)
Hypothermia — no. (%) 27 (3.5) 25 (3.2) 52 (3.3)
Median blood pressure (IQR) — mm Hg
Systolic 92 (85–98) 92 (85–99) 92 (85–99)
Diastolic 56 (49–63) 55 (49–63) 56 (49–63)
Median oxygen saturation (IQR) — % 98 (97–99) 98 (96–99) 98 (97–99)
Median respiratory rate (IQR) — breaths/min 38 (32–44) 38 (32–46) 38 (32–46)
Shock — no. (%)‡ 100 (12.9) 112 (14.2) 212 (13.5)
Severe dehydration — no. (%)§ 38 (4.9) 29 (3.7) 67 (4.3)
HIV positivity — no./total no. (%) 15/736 (2.0) 17/736 (2.3) 32/1472 (2.2)
Malaria slide or RDT positivity — no. (%) 497 (63.9) 487 (61.9) 984 (62.9)
Positive blood culture — no./total no. (%) 29/702 (4.1) 33/696 (4.7) 62/1398 (4.4)
Median C-reactive protein level (IQR) — mg/dl 54.2 (19.1–100.2) 55.8 (18.9–107.4) 54.9 (19.0–101.3)
Lactate level — mmol/liter 2.4 (1.7–3.2) 2.3 (1.7–3.2) 2.3 (1.7–3.2)
Previous blood transfusion in current illness — no. (%) 11 (1.4) 7 (0.9) 18 (1.2)
Blood transfusion ever 194 (24.9) 150 (19.1) 344 (22.0)
Sickle cell disease identified after randomization — no. (%)¶ 0 7 (0.9) 7 (0.4)
Sickle cell disease identified by batch genotyping after the end  
of the trial — no./total no. (%)‖
172/772 (22.3) 168/777 (21.6) 340/1549 (21.9)
*  There were no significant between-group differences in the baseline characteristics except for oxygen saturation (P = 0.005) and blood trans-
fusion ever (P = 0.006). HIV denotes human immunodeficiency virus, IQR interquartile range, and RDT rapid diagnostic test.
†  Axillary temperature was measured with a digital thermometer. Fever was defined as a temperature higher than 37.5°C, and hypothermia as 
a temperature lower than 36.0°C.
‡  Shock was defined as any one of the following: capillary refill time of more than 2 seconds, a lower-limb temperature gradient (a positive 
temperature gradient was indicated if the peripheral limb was cooler than the thigh), or weak pulse.
§  Severe dehydration was defined by skin turgor or sunken eyes.
¶  In this population of children who were hospitalized for uncomplicated severe anemia, sickle cell disease was identified in 7 children in the 
control group during their primary hospitalization on the basis of further questioning by the caregiver after the obtaining of consent and 
randomization (4 children) and after the development of clinical symptoms (3 children).
‖  The results of batch genotyping of admission blood samples after the end of the trial were missing for 16 children.
Table 1. Characteristics of the Children at Baseline.*
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(Table S3 in the Supplementary Appendix). By 
day 180, death had occurred in 35 children 
(4.5%) in the immediate-transfusion group and 
47 (6.0%) in the control group (hazard ratio, 
0.75; 95% CI, 0.48 to 1.15). The causes of death 
and the results of subgroup analyses are pro-
Outcome
Immediate-
Transfusion Group 
(N = 778)
Control Group 
(N = 787)
Total 
(N = 1565)
Hazard Ratio 
(95% CI)† P Value
Death — no. (%)
At 48 hours‡ 0 2 (0.3) 2 (0.1)
At 28 days: primary outcome 7 (0.9) 13 (1.7) 20 (1.3) 0.54 (0.22–1.36) 0.19
At 90 days‡ 24 (3.1) 31 (3.9) 55 (3.5) 0.78 (0.46–1.32)
At 180 days‡ 35 (4.5) 47 (6.0) 82 (5.2) 0.75 (0.48–1.15)
Correction of anemia — no. (%)‡ 399 (51.3) 43 (5.5) 442 (28.2) 11.73 (8.69–15.84)§
Development of new profound anemia during the 
primary hospitalization — no. (%)‡
11 (1.4) 309 (39.3) 320 (20.4) 0.03 (0.02–0.05)§
Development of severe anemia after discharge  
— no. (%)‡
106 (13.6) 142 (18.0) 248 (15.8) 0.73 (0.56–0.94)§
Readmission to hospital — no. (%)‡ 123 (15.8) 113 (14.4) 236 (15.1) 1.09 (0.84–1.40)§
Serious adverse event‡
At least one event — no. of patients (%) 152 (19.5) 151 (19.2) 303 (19.4) 1.02 (0.82–1.28) 0.85
No. of events 198 201 399
Type of serious adverse event
Anemia¶
At least one event — no. of patients (%) 78 (10.0) 83 (10.5) 161 (10.3) 0.74‖
No. of events 97 107 204
Malaria
At least one event — no. of patients (%) 54 (6.9) 51 (6.5) 105 (6.7) 0.76‖
No. of events 61 56 117
Sepsis
At least one event — no. of patients (%) 22 (2.8) 28 (3.6) 50 (3.2) 0.47‖
No. of events 27 33 60
Hemoglobinuria
At least one event — no. of patients (%) 24 (3.1) 15 (1.9) 39 (2.5) 0.15‖
No. of events 27 16 43
Suspected allergic reactions — no. (%)‡** 6 (0.8) 2 (0.3) 8 (0.5) 0.17‖
Suspected pulmonary overload, transfusion-related 
acute lung injury, or transfusion-related 
cardiac overload — no.‡
0 0 0
*  Correction of anemia was defined as hemoglobin recovery to a level greater than 9 g per deciliter during the primary hospitalization. Profound 
anemia was defined as a hemoglobin level of less than 4 g per deciliter. Severe anemia was defined as a hemoglobin level of less than 6 g 
per deciliter.
†  Hazard ratios are for the immediate-transfusion group as compared with the control group. Confidence intervals have not been adjusted 
for multiple testing, and inferences drawn from the intervals may not be reproducible.
‡  This is a secondary outcome that was prespecified in the protocol. The P value is not reported except for adverse events.
§  This hazard ratio was estimated with the use of subhazard regression allowing for competing risks.
¶  The diagnosis of the serious adverse event of anemia (including anemia-related death) was made by the attending clinician (during the 
primary hospitalization and after discharge). There was no formal hemoglobin threshold required.
‖  The P value was calculated with the use of Fisher’s exact test.
**  The grades of suspected allergic reactions are provided in Table S6 in the Supplementary Appendix.
Table 2. Primary, Secondary, and Other Outcomes.*
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vided in the Results section in the Supplemen-
tary Appendix.
Hemoglobin Recovery
As expected, increases in the hemoglobin level 
during the first 48 hours after randomization 
were substantially greater in the immediate-
transfusion group than in the control group 
(Fig. 2B and 2C). At 48 hours, the mean hemo-
globin level was higher by 2.42 g per deciliter 
(95% CI, 2.17 to 2.67) in the immediate-transfu-
sion group than in the control group, with a 
mean hemoglobin level of 8.4±1.7 g per deciliter 
in the immediate-transfusion group, as compared 
with 7.0±1.7 g per deciliter among the 249 chil-
dren in the control group who received a trans-
fusion before 48 hours and 5.5±1.1 g per deci-
liter among the 535 children in control group who 
did not. In the control group, the children who 
received a transfusion 12 hours or more after 
randomization and those who received a trans-
fusion within 12 hours had similar increases in 
the hemoglobin level at 48 hours (Fig. S3 in the 
Supplementary Appendix). During the primary 
hospitalization, hemoglobin recovery to a level 
greater than 9 g per deciliter occurred faster in 
the immediate-transfusion group than in the con-
trol group, and new profound anemia (hemoglo-
bin level <4 g per deciliter) occurred less fre-
quently in the immediate-transfusion group 
(Table 2, and Fig. S4 in the Supplementary Ap-
pendix). The differences in hemoglobin level be-
tween the randomization groups had attenuated 
substantially at 28 days (0.60 g per deciliter 
[95% CI, 0.35 to 0.86] higher in the immediate-
transfusion group) and 90 days (0.48 g per deci-
liter [95% CI, 0.22 to 0.73] higher in the imme-
diate-transfusion group). At day 180, there was 
no evidence of differences in the mean hemoglo-
bin level between the two groups (0.23 g per 
deciliter [95% CI, −0.03 to 0.49] higher in the 
immediate-transfusion group) or in the percent-
ages of children who had hemoglobin levels of 
9 g per deciliter or lower or of less than 6 g per 
deciliter (Fig. 2B and 2C).
Other Clinical Outcomes
The median length of hospital stay was 3 days 
(interquartile range, 3 to 4) in the immediate-
transfusion group and 4 days (interquartile range, 
3 to 6) in the control group (hazard ratio for 
time to discharge, 1.62; 95% CI, 1.46 to 1.80) 
(Fig. S5 in the Supplementary Appendix), with a 
mean of 4.0 and 4.9 hospitalization days, respec-
tively, during the primary hospitalization. By day 
180, a total of 123 children (15.8%) in the imme-
diate-transfusion group and 113 children (14.4%) 
in the control group had been readmitted to the 
hospital (hazard ratio for readmission, 1.09; 95% 
CI, 0.84 to 1.40) (Table 2, and Fig. S6 in the 
Supplementary Appendix), mostly because of ane-
mia, malaria, or sepsis. Serious adverse events 
occurred in 152 children (19.5%) in the immedi-
ate-transfusion group and in 151 children (19.2%) 
in the control group (P = 0.85) (Table 2, and Table 
S5 in the Supplementary Appendix). Transfusion-
specific serious adverse events included non–
life-threatening allergic events in 6 children in 
the immediate-transfusion group and 2 children 
in the control group (Table S6 in the Supplemen-
tary Appendix).
Costs and Cost-Effectiveness
The main cost drivers were length of hospital 
stay (mean cost, $29.70 in the immediate-trans-
fusion group and $34.30 in the control group), 
blood transfusions (mean cost, $22.20 and 
$11.78, respectively [half of children in the con-
trol group received a transfusion]), and hemo-
globin tests (mean cost, $8.46 and $8.41, respec-
tively); the total unadjusted costs per child were 
$72.09 in the immediate-transfusion group and 
$66.46 in the control group — $5.63 less in the 
control group (Tables S6 through S8 in the Sup-
plementary Appendix). Sensitivity analyses sug-
gested that the total unadjusted savings might 
increase to $22.80 if standard blood units (450 ml) 
Figure 2 (facing page). Key Outcomes, Admission 
through 180 Days.
The time window for the 180-day visit was 120 to 240 
days after randomization (99.3% of the children were 
seen after 170 days). The inset in Panel A shows the 
same data on an enlarged y axis. Panel B shows the 
mean hemoglobin level during the first 48 hours and 
through 180 days. Panel C shows distribution of hemo-
globin levels of less than 6 g per deciliter, 6 to 9 g per 
deciliter, and higher than 9 g per deciliter according to 
the indicated time point. Additional details are provided 
in Table S4A and S4B in the Supplementary Appendix.
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were used, if blood costs were higher, or both. 
Total unadjusted costs were similar if no hemo-
globin tests were performed in the immediate-
transfusion group and two hemoglobin tests 
were performed in the control group within 48 
hours from randomization (Table S10 in the 
Supplementary Appendix). Life-years gained over 
a period of 180 days were similar in the imme-
diate-transfusion group (0.487) and the control 
group (0.482). Overall, the triggered-transfusion 
strategy used in the control group was less 
costly than the immediate-transfusion strategy, 
although the triggered-transfusion strategy was 
estimated to be less effective (Table S11 in the 
Supplementary Appendix).
Predictors of Transfusion in the Control 
Group
The time to transfusion was assessed among 776 
children in the control group, with the exclusion 
of 11 children who were identified after random-
ization as having severity criteria at admission 
(7 had sickle cell disease [all of whom received 
a transfusion], and 4 had preexisting hemoglobin-
uria [3 of whom received a transfusion]). A total 
of 348 children (44.8%) received a transfusion by 
96 hours. The hemoglobin level at admission was 
the strongest predictor (Table S12 in the Supple-
mentary Appendix); 79.3% of the children who 
had a hemoglobin level of 4.5 g per deciliter or 
lower received a transfusion, and 35.4% of those 
who had a hemoglobin level higher than 4.5 g 
per deciliter received a transfusion (Fig. 3). Per-
forming transfusion in all the children who had 
a hemoglobin level of 4.5 g per deciliter or lower 
(23.1% of the children in the control group) 
would have covered 142 (40.8%) of the triggered 
transfusions performed. There was no evidence 
that undiagnosed sickle cell disease had an ef-
fect on whether children received a transfusion. 
Predictors of transfusion for a hemoglobin level 
of less than 4 g per deciliter were similar to 
predictors of transfusion for any reason (data 
not shown).
Discussion
Although mortality was too low to either show 
or refute any benefits from immediate transfu-
sion, our large, multicenter trial showed that 
among children with uncomplicated severe ane-
mia, the immediate-transfusion strategy resulted 
in fewer children who had development of pro-
found anemia (hemoglobin level <4 g per deci-
liter), which is an absolute indication for transfu-
sion, and more children who had early hemoglobin 
Figure 3. Transfusion Status among the Children in the Control Group, Stratified According to Baseline Hemoglobin Level.
The percentages above the bars represent the percentage of children who received a transfusion among those who had the indicated 
 hemoglobin level at baseline.
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recovery (to a level >9 g per deciliter) than the 
triggered-transfusion strategy. However, these 
findings in the immediate-transfusion group did 
not translate into fewer readmissions (15.1% of 
the children) or fewer serious adverse events re-
lated to anemia (10.3% of the children).
A key limitation of this trial was the lower 
overall mortality (2%) than the 9% predicted ac-
cording to other studies of uncomplicated severe 
anemia in African children, which showed con-
sistently higher mortality.3,21,22 One reason may 
be that screening was halted when no donor 
blood units were available; thus, in contrast to 
previous reports,8,21,22 no child in the trial died 
while waiting for a transfusion. Hemoglobin 
monitoring during the trial may have also im-
proved outcomes. Hemovigilance detected very 
few adverse reactions to transfusion. Clinical and 
hemoglobin monitoring (every 8 hours during 
the first 24 hours and then at 48 hours or if trig-
gered by clinical deterioration) identified new 
severity criteria that warranted transfusion in the 
control group, leading to 49.0% of the children 
in the control group receiving a potentially life-
saving transfusion (93.5% of whom received a 
transfusion according to the protocol), although 
the transfusions were performed substantially 
later than had they been in the immediate-
transfusion group. The WHO guidelines were 
based largely on observational studies7,21,22 and 
recommend not performing transfusion in pa-
tients with uncomplicated severe anemia. The 
guidelines, however, do not address either clini-
cal or hemoglobin monitoring during hospital-
ization or anticipate the development of compli-
cated severe anemia after admission. In this 
trial, we did not withhold transfusion in the 
patients in the control group who had develop-
ment of complicated severe anemia, because this 
would be unethical and inconsistent with good 
clinical practice. However, our approach also 
may have led to lower mortality than originally 
hypothesized. Therefore, the control group in 
TRACT reflected a pragmatic strategy of con-
serving blood for the children who were identi-
fied after admission as being at high risk. The 
low mortality in the control group suggests that 
clinical and hemoglobin monitoring may be im-
portant in reducing poor outcomes, as compared 
with not performing transfusion at all. However, 
the trial retained good power to assess the rates 
of readmissions. Strategies to prevent readmis-
sions should therefore be a key focus in future 
interventional trials to reduce morbidity in this 
high-risk group.
The guidelines that have received worldwide 
consensus regarding transfusion in children in 
stable condition in intensive care units recom-
mend transfusion in those who have a hemoglo-
bin level of less than 7 g per deciliter23 but ex-
plicitly highlight the need for further trials, 
particularly those involving children who have a 
hemoglobin level of 5 to 7 g per deciliter.7 Chil-
dren in high-income countries probably have 
steady-state hemoglobin levels of 11 to 14 g per 
deciliter, whereas African children in areas where 
malaria and α+-thalassemia are common24 typi-
cally have hemoglobin levels of 9 to 11 g per 
deciliter.4,25 The effect of lower thresholds for 
immediate transfusion in Africa may therefore 
reflect differences in steady-state hemoglobin 
levels. We cannot exclude a small mortality bene-
fit with immediate transfusion among the chil-
dren in our trial; however, 7 of the 13 deaths in 
the control group occurred in children who re-
ceived a transfusion within 10 hours after ran-
domization, and we found no evidence of differ-
ences in morbidity between the two groups. 
Given the burden of pediatric severe anemia in 
sub-Saharan Africa, the strategy of immediate 
transfusion in children with uncomplicated se-
vere anemia has the potential to overburden the 
blood-transfusion services, as compared with 
close monitoring and targeted transfusion.
Nevertheless, the length of hospital stay was 
longer among the children in the control group 
than among those in the immediate-transfusion 
group, with potential implications for out-of-
pocket costs for parents. Hemoglobin monitor-
ing also uses resources (financial and staff), al-
though at a lower rate than blood transfusion 
(the estimated costs were approximately $20 per 
blood unit vs. approximately $1 per hemoglobin 
test). Overall, the triggered-transfusion strategy 
resulted in a lower cost than the immediate-
transfusion strategy but was also slightly less ef-
fective, which makes triggered transfusion with 
clinical and hemoglobin monitoring the cost-
effective option.
An important limitation in this trial was the 
lack of hemoglobin measurements after 48 hours 
from admission and specifically at discharge. 
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Other limitations of this trial include the sub-
stantial uncertainty regarding the costs of blood 
units, which vary according to country, the size 
and type of blood units (Table S7 in the Supple-
mentary Appendix),26 and the costs of hemoglobin 
monitoring. Our within-trial economic analysis 
did not evaluate longer-term risks and benefits, 
which could change the value-for-money esti-
mates. Ideally, greater efforts should be put into 
achieving an adequate and reliable blood supply. 
However, health services should consider the op-
tion of regular measurements of hemoglobin for 
monitoring and continuing the restrictive trans-
fusion strategy in the WHO guidelines to avert 
the more substantial costs to the blood-transfu-
sion services of providing immediate blood trans-
fusion to all children who have a hemoglobin 
level of 4 to 6 g per deciliter.
The strengths of this trial include the broad 
eligibility criteria, which enhanced generalizabil-
ity; the inclusion of a large subgroup of children 
with malaria; and high adherence to the assigned 
transfusion strategy (94%) and follow-up (>95%). 
The burden of hidden sickle cell disease, which 
was identified in 21.7% of the children with 
uncomplicated severe anemia after the end of 
this trial, should prompt universal screening of 
admitted children with severe anemia.27 It is re-
assuring that undiagnosed sickle cell disease did 
not predict transfusion in the control group, 
which indicates that sickle cell disease without 
life-threatening complications can be managed 
without immediate transfusion.
Overall, there was no evidence of differences 
in clinical outcomes between the children who 
received immediate transfusion and those who 
did not. The triggered-transfusion strategy in the 
control group resulted in 60% lower blood use; 
however, the length of hospital stay was 20% 
longer, and this strategy required clinical and 
hemoglobin monitoring. Although we cannot 
rule out the possibility of a small mortality bene-
fit with immediate transfusion, mortality was 
very low with both strategies, and immediate 
transfusion failed to lower the rate of readmis-
sion during the following 6 months, which re-
mained high in both groups.
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